Novartis AG (NVS) Stock Price & Analysis
Novartis AG (NVS) closed at USD 156.27 on Thursday, October 22, 2026, up 1.52% on the day. The US market is currently closed (pre-market); this is not a live price.
The prior close was USD 153.93; the Oct 22, 2026 session ranged USD 154.38–157.1 on volume of 2,081,330 shares. Market capitalization is $297.02B, with a 52-week range of USD 121.57–170.46 (NYQ). Source: Nexqual, retrieved October 23, 2026 at 09:24 UTC.
Also available as compact Markdown for AI agents: nexqual.com/NVS.md
Key facts (NVS)
- 5 of 80 tracked superinvestors hold NVS (13F, Q2 2026): 0 new, 2 added, 2 reduced, 1 unchanged.
- Analysts: Hold (mean 2.58 on a 1–5 scale) (12 analysts), mean target USD 154.65 (range 130–185).
- Total return with dividends: 1Y +22.3% vs S&P 500 +14.9%; 5Y +121.9% vs S&P 500 +80.3%.
- Next earnings: 2026-10-27, EPS estimate USD 2.24, revenue estimate $14.6B.
Superinvestors (SEC 13F-HR, Q2 2026) (NVS)
5 of 80 tracked investors hold NVS. Each row is the investor's latest 13F; change is vs their prior-quarter share count.
| Investor | Firm | % of portfolio | Value | Change |
|---|---|---|---|---|
| Tweedy Browne | 0.84% | $11.1M | Reduced -0.3% | |
| Kahn Brothers | Kahn Brothers Group | 0.36% | $2.0M | Unchanged |
| Dodge & Cox Funds | Dodge & Cox | 0.06% | $119M | Reduced -89.1% |
| Lee Ainslie | Maverick Capital | 0.04% | $4.4M | Added +82.3% |
| Sarah Ketterer | Causeway Capital Management | <0.01% | $235K | Added +0.9% |
Analysts (NVS)
Consensus Hold (mean 2.58 on a 1–5 scale), 12 analysts; mean target USD 154.65 (low 130, high 185).
Rating changes, last 120 days:
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-09-10 | HSBC | Upgrade | Reduce → Hold | $123 → $136 |
Total return (dividends reinvested) (NVS)
| 1Y (from 2025-10-23) | 5Y (from 2021-10-18) | |
|---|---|---|
| Total return | +22.3% | +121.9% |
| S&P 500 (SPY) | +14.9% | +80.3% |
| Per year | +22.4% | +17.2% |
| Volatility (annualized) | 27.3% | 20.8% |
| Max drawdown | -16.2% (Feb 2026→Sep 2026) | -19.7% (Aug 2024→Dec 2024) |
Companies that name NVS in their SEC reports
| Relationship to NVS | Company | Filing | Sentence |
|---|---|---|---|
| partner | Cellectis S.A. (CLLS) | 20-F Mar 20, 2026 | “Autologous and Allogeneic CAR T-cell space: Bristol-Myers Squibb, Gilead Sciences Inc., Novartis AG, Johnson & Johnson, Regeneron Pharmaceuticals Inc., Fate Therapeutics Inc., CRISPR Therapeutics Inc., Caribou Biosciences Inc., Takeda Pharmaceutical Company Limited, Mustang Bio, Atara Biotherapeutics Inc., Adaptimmune (in collaboration with Astellas), Poseida Therapeutics Inc. (acquired by F.” |
| partner | Mereo BioPharma Group plc (MREO) | 10-K Mar 19, 2026 | “We have strong relationships with these companies, as evidenced by our agreements with Novartis AG ("Novartis") and AstraZeneca AB ("AstraZeneca"), as well as our partnership with Ultragenyx, and a track record of structuring transactions that enable us to leverage our core capabilities while creating value for all stakeholders.” |
| partner | Monte Rosa Therapeutics, Inc. (GLUE) | 10-K Mar 17, 2026 | “the potential benefits of strategic collaborations and our ability to enter into strategic collaborations with third parties who have the expertise to enable us to further develop our biological targets, product candidates and discovery engine technologies, including our agreements with Novartis AG, or Novartis, for MRT-6160 and other discovery programs and our agreement with F.” |
| supplier | Rallybio Corp (RLYB) | 10-K Mar 16, 2026 | “Prior to Novartis, Ms. Boudreau served in roles of increasing responsibility in strategy and finance at Pfizer Inc. ("Pfizer") from April 1999 to September 2008, including Vice President Finance Customer Business Unit and Commercial Operations and Vice President Finance, Pfizer Global Research and Development.” |
| partner | MOLECULAR PARTNERS AG (MOLN) | 20-F Mar 12, 2026 | “For example in January 2024, Novartis, our collaboration partner for ensovibep, informed us of its decision to return the global rights for ensovibep to us following the end of COVID-19 pandemic.” |
| partner | GSK plc (GSK) | 20-F Mar 6, 2026 | “The consideration payable for the acquisition of the Shionogi-ViiV Healthcare joint venture, Affinivax, the Novartis Vaccines” |
| partner | REGENXBIO Inc. (RGNX) | 10-K Mar 5, 2026 | “Royalty revenue to date consists primarily of royalties on net sales of Zolgensma and Itvisma, which are licensed products under the Company's license agreement with Novartis Gene Therapies, Inc. (Novartis Gene Therapies), a wholly owned subsidiary of Novartis AG (Novartis), for the development and commercialization of treatments for spinal muscular atrophy (SMA).” |
| partner | Ocugen, Inc. (OCGN) | 10-K Mar 4, 2026 | “We are aware of several companies focusing on gene therapies for various ophthalmic indications including Applied Genetic Technologies Corporation, as acquired by Beacon Therapeutics, Astellas Pharma Inc., MeiraGTx Holdings plc in partnership with Janssen Pharmaceuticals, Inc., Nanoscope Therapeutics Inc., REGENXBIO Inc., Novartis AG, F.” |
| partner | Arcus Biosciences, Inc. (RCUS) | 10-K Feb 25, 2026 | “There are many other companies that have commercialized and/or are developing oncology treatments for cancer including large pharmaceutical and biotechnology companies such as AstraZeneca, BeiGene, Ltd. ("BeiGene"), The Bristol-Myer Squibb Company ("Bristol-Myers Squibb"), GlaxoSmithKline plc ("GSK"), Merck, Novartis Inc. ("Novartis"), Pfizer Inc. ("Pfizer"), Regeneron Pharmaceuticals, Inc. ("Regeneron") in partne…” |
| partner | ALNYLAM PHARMACEUTICALS, INC. (ALNY) | 10-K Feb 12, 2026 | “Leqvio (inclisiran) is being developed and commercialized by our collaborator Novartis AG, or Novartis, and has received marketing authorization from the European Commission, or EC, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia and from the FDA as an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia, or H…” |
NVS analyst estimates and revisions
| Period | EPS estimate | 90 days ago | Change | Revenue estimate | Analysts |
|---|---|---|---|---|---|
| Current quarter (ends Sep 2026) | $2.24 | $2.20 | +1.9% | $14.61B | 3 |
| Next quarter (ends Dec 2026) | $2.22 | $2.32 | -4.1% | $14.99B | 3 |
| Current fiscal year (ends Dec 2026) | $8.83 | $8.68 | +1.7% | $57.64B | 9 |
| Next fiscal year (ends Dec 2027) | $9.80 | $9.75 | +0.5% | $61.32B | 10 |
NVS options: expected move
Options price a move of about ±6.5% (±$10.20) by Nov 20, 2026, which includes earnings on Oct 27, 2026.
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 28.8% | ±6.5% |
| Dec 18, 2026 | 56 | 26.6% | ±8.4% |
| Jan 15, 2027 | 84 | 25.3% | ±9.9% |
| Apr 16, 2027 | 175 | 26.4% | ±15.2% |
| Jun 17, 2027 | 237 | 25.1% | ±16.3% |
30-day implied volatility 28.1% vs 17.9% realized over the last 30 trading days. Put/call ratio (volume) 24.18. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 09:24 UTC)
| Price | USD 156.27 |
|---|---|
| Change | ▲ 1.52% (up) |
| Previous Close | USD 153.93 |
| Open | USD 154.9 |
| Day Range | USD 154.38 – 157.1 |
| 52-Week Range | USD 121.57 – 170.46 |
| Volume | 2,081,330 shares |
| Market Cap | $297.02B |
| Exchange | NYQ |
Technical Analysis (NVS)
Nexqual's technical model rates NVS "BUY" based on 5 bullish and 2 bearish signals across 127 daily candles, as of October 23, 2026 at 09:24 UTC.
| Overall Signal | BUY |
|---|---|
| RSI (14) | 62.8 (neutral) |
| vs SMA50 | Above (USD 148.12) |
| MACD | 2.07 (positive) |
Analyst Ratings (NVS)
Wall Street analysts rate NVS "Hold" based on 12 analysts, with a mean price target of USD 154.65 (range USD 130–185), per Nexqual as of October 23, 2026 at 09:24 UTC.
| Consensus Rating | Hold |
|---|---|
| Analyst Count | 12 |
| Mean Target | USD 154.65 |
| High Target | USD 185 |
| Low Target | USD 130 |
| Buy / Hold / Sell | 5 / 5 / 2 |
Earnings (NVS)
| Next Earnings Date | 2026-10-27 |
|---|---|
| EPS Estimate | USD 2.24 |
| Revenue Estimate | $14.61B |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-06-30 | USD 2.41 vs est 2.15 ▲ beat |
| 2026-03-31 | USD 1.99 vs est 2.07 ▼ miss |
| 2025-12-31 | USD 2.03 vs est 2 ▲ beat |
| 2025-09-30 | USD 2.25 vs est 2.31 ▼ miss |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financials & Fundamentals (NVS)
| Total Revenue | $56.69B |
|---|---|
| Revenue Growth (latest quarter, YoY) | +0.80% |
| Gross Margin | +74.98% |
| Operating Margin | +34.62% |
| Profit Margin | +22.50% |
| ROE | +30.35% |
| Debt / Equity | 1.17 |
| Current Ratio | 0.86 |
| Total Cash | $7.62B |
| Total Debt | $49.01B |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Financial Health Score (NVS)
Nexqual rates Novartis AG's overall financial health "Solid" across five dimensions, as of October 23, 2026 at 09:24 UTC.
| Growth | Solid — Revenue +10% YoY (annual) |
|---|---|
| Profitability | Strong — Gross margin 75%, operating 35% (last 12 months) |
| Balance Sheet | Weak — $7.62B cash vs $49.0B debt |
| Cash Flow | Solid — Operating cash flow $18.4B (TTM) |
| Efficiency | Strong — ROE 30%, ROA 10.3% |
Ownership (NVS)
| Insider Ownership | +0.01% |
|---|---|
| Institutional Ownership | +7.26% |
| Shares Outstanding | 1.90B |
| Float | 1.86B |
| Short % of Float | +0.30% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Leadership (NVS)
Novartis AG is led by Vasant Narasimhan, Chief Executive Officer, per Nexqual as of October 23, 2026 at 09:24 UTC.
| Chief Executive Officer | Vasant Narasimhan |
|---|---|
| President of US | Victor Bulto |
| President of International | Patrick Horber |
| Chief Financial Officer | Mukul Mehta |
| President of Operations | Steffen Lang |
Major Backers & Investors (NVS)
Notable institutional backers of Novartis AG include Fisher Asset Management, LLC, Morgan Stanley, Primecap Management Company, according to Nexqual as of October 23, 2026 at 09:24 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Fisher Asset Management, LLC | 0.76% |
| Morgan Stanley | 0.43% |
| Primecap Management Company | 0.32% |
| LOOMIS SAYLES & CO L P | 0.26% |
| Bank of America Corporation | 0.24% |
| Franklin Resources, Inc. | 0.16% |
| Goldman Sachs | 0.15% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| Dimensional Fund Advisors | 0.4% |
| Vanguard Group | 0.27% |
| BlackRock | 0.15% |
Source: Nexqual, October 23, 2026 at 09:24 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| AZN | AstraZeneca PLC | USD 172.57 | ▲ 2.45% |
| MRK | Merck & Company, Inc. | USD 147.24 | ▼ 1.76% |
| AMGN | Amgen Inc. | USD 447.28 | ▲ 2.04% |
| GILD | Gilead Sciences, Inc. | USD 157.19 | ▲ 2.36% |
| ABBV | AbbVie Inc. | USD 285.19 | ▲ 0.14% |
| NVO | Novo Nordisk A/S | USD 39.43 | ▲ 0.95% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 09:24 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt